Edge cases. The big picture is that it's not happening fast enough, which is why the government will need to step in and will need to assume a leadership role to push hard on this.
That's not going to happen. The gov't will change the regulatory and reimbursement environment but the heavy lifting will be done by academic and pharmaceutical researchers.